Augmedix, Inc. (NASDAQ:AUGX - Get Free Report) insider Ian Shakil sold 37,780 shares of the firm's stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $3.97, for a total transaction of $149,986.60. Following the completion of the transaction, the insider now directly owns 3,000 shares in the company, valued at approximately $11,910. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Ian Shakil also recently made the following trade(s):
- On Friday, April 5th, Ian Shakil sold 51,387 shares of Augmedix stock. The stock was sold at an average price of $4.03, for a total transaction of $207,089.61.
- On Wednesday, April 3rd, Ian Shakil sold 45,906 shares of Augmedix stock. The stock was sold at an average price of $4.11, for a total transaction of $188,673.66.
- On Monday, April 1st, Ian Shakil sold 58,978 shares of Augmedix stock. The stock was sold at an average price of $3.91, for a total transaction of $230,603.98.
- On Thursday, March 28th, Ian Shakil sold 31,994 shares of Augmedix stock. The stock was sold at an average price of $4.06, for a total transaction of $129,895.64.
Augmedix Stock Up 1.0 %
AUGX opened at $4.06 on Wednesday. The company has a fifty day moving average price of $4.17 and a 200-day moving average price of $4.85. The firm has a market capitalization of $197.88 million, a P/E ratio of -9.02 and a beta of -0.16. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.41 and a quick ratio of 2.41. Augmedix, Inc. has a one year low of $1.50 and a one year high of $6.25.
Elon to Transform U.S. Economy?
From Porter & Company | Ad
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites.
And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
One company holds a near-total monopoly on it.
Augmedix (NASDAQ:AUGX - Get Free Report) last posted its quarterly earnings data on Monday, March 18th. The company reported ($0.09) earnings per share (EPS) for the quarter. Augmedix had a negative return on equity of 308.50% and a negative net margin of 42.74%. The company had revenue of $12.68 million for the quarter, compared to the consensus estimate of $12.30 million. Equities research analysts expect that Augmedix, Inc. will post -0.51 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
AUGX has been the topic of several recent analyst reports. B. Riley initiated coverage on shares of Augmedix in a research report on Wednesday, April 3rd. They set a "buy" rating and a $5.50 target price on the stock. Maxim Group lowered their price target on shares of Augmedix from $6.50 to $5.00 and set a "buy" rating on the stock in a report on Tuesday, March 19th. Finally, Evercore ISI raised shares of Augmedix from an "in-line" rating to an "outperform" rating and lifted their price target for the stock from $4.50 to $5.00 in a report on Tuesday.
Get Our Latest Stock Analysis on AUGX
Institutional Trading of Augmedix
A number of hedge funds have recently made changes to their positions in AUGX. Portside Wealth Group LLC bought a new stake in shares of Augmedix during the 2nd quarter worth $286,000. Tucker Asset Management LLC bought a new stake in Augmedix in the second quarter worth $172,000. Vontobel Holding Ltd. lifted its stake in Augmedix by 439.7% in the third quarter. Vontobel Holding Ltd. now owns 173,209 shares of the company's stock worth $892,000 after purchasing an additional 141,113 shares during the last quarter. Legato Capital Management LLC bought a new stake in Augmedix in the third quarter worth $840,000. Finally, Taylor Frigon Capital Management LLC bought a new stake in Augmedix in the third quarter worth $438,000. 87.11% of the stock is owned by institutional investors.
Augmedix Company Profile
(
Get Free Report)
Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
